Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

53 results about "Neuroactive steroid" patented technology

Neurosteroids, also known as neuroactive steroids, are endogenous or exogenous steroids that rapidly alter neuronal excitability through interaction with ligand-gated ion channels and other cell surface receptors. The term neurosteroid was coined by the French physiologist Étienne-Émile Baulieu and refers to steroids synthesized in the brain. The term, neuroactive steroid refers to steroids that can be synthesized in the brain, or are synthesized by an endocrine gland, that then reach the brain through the bloodstream and have effects on brain function. The term neuroactive steroids was first coined in 1992 by Steven Paul and Robert Purdy. In addition to their actions on neuronal membrane receptors, some of these steroids may also exert effects on gene expression via nuclear steroid hormone receptors. Neurosteroids have a wide range of potential clinical applications from sedation to treatment of epilepsy and traumatic brain injury. Ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, is under investigation for the treatment of epilepsy.

Crystal form of neuroactive steroid derivative and application thereof

The invention provides a crystal form of a neuroactive steroid derivative and application thereof, and belongs to the technical field of medicines. The crystal form of the neuroactive steroid derivative (with the structure as shown in the formula I) provided by the invention is radiated by Cu-K alpha, and characteristic diffraction peaks of an X-ray powder diffraction pattern expressed by a 2 theta angle comprise 11.450 + / -0.200 degrees, 15.724 + / -0.200 degrees, 19.040 + / -0.200 degrees, 22.955 + / -0.200 degrees and 24.975 + / -0.200 degrees. The crystal form provided by the invention has the advantages of good fluidity, no electrostatic phenomenon, high stability and almost no hygroscopicity, and can stably exist under the conditions of high temperature, high humidity and illumination; the compound has a relatively strong positive regulation effect on a GABAA receptor, has relatively good pharmacokinetic properties and oral absorption rate, and can be applied to preparation of oral and other dosage form medicines for efficiently resisting diseases such as postpartum depression. # imgabs0 #
Owner:HUNAN MINGRUI PHARMACEUTICAL CO LTD

Neuroactive steroids for treatment of CNS-related disorders

PendingUS20250295674A1Organic active ingredientsNervous disorderPost-pregnancy depressionDisease
The present disclosure relates to methods of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof with a combination of Compound (1) and an additional antidepressant, followed by continued administration of the additional antidepressant.
Owner:SAGE THERAPEUTICS LLC

Neuroactive steroid for the treatment of huntington's disease

Provided herein are methods for improving working memory and / or executive function in a subject suffering from Huntington's Disease, comprising administering to the subject SAGE-718, an investigational positive allosteric modulator of the NMDA receptor.
Owner:SAGE THERAPEUTICS INC

Neuroactive steroids, compositions, and uses thereof

PendingUS20260116912A1Organic active ingredientsNervous disorderWithdrawal syndromeSubstance abuser
Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS INC

Neuroactive steroid solid dispersion, solid dispersion composition, preparation method and application thereof, and medicine containing solid dispersion

The present invention provides a neuroactive steroid solid dispersion, a solid dispersion composition, a preparation method and application, and a drug containing the solid dispersion, and belongs to the field of pharmaceutical technology. The present invention melt-extrudes a raw material mixture to obtain a neuroactive steroid solid dispersion; the raw material mixture includes 10 to 70 parts of neuroactive steroids, 30 to 90 parts of carrier materials, and 0 to 60 parts of plasticizers by mass; the temperature of the melt extrusion is <160°C; the neuroactive steroid in the neuroactive steroid solid dispersion exists in an amorphous state, and the particle size of the neuroactive steroid in the neuroactive steroid solid dispersion is ≤200nm. The neuroactive steroid in the neuroactive steroid solid dispersion provided by the present invention has a high oral bioavailability.
Owner:BEIJING HORICIN BIOTECHNOLOGY CO LTD

Neuroactive steroids, compositions, and uses thereof

InactiveUS20260116911A1Organic active ingredientsNervous disorderWithdrawal syndromeSubstance abuser
Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS INC

Neuroactive steroid solid dispersion, solid dispersion composition, method for preparing same and use thereof, and drug comprising solid dispersion

The present invention relates to the field of pharmaceutical technology, and in particular, to a neuroactive steroid solid dispersion, a solid dispersion composition, a method for preparing same and use thereof, and a medicament comprising the solid dispersion. The neuroactive steroid solid dispersion is obtained by melting and extruding a mixture of raw materials. In parts by mass, the mixture of raw materials comprises: 10 to 70 parts of a neuroactive steroid, 30 to 90 parts of a carrier material, and 0 to 60 parts of a plasticizer. The temperature of melting and extruding is < 160 °C. The neuroactive steroid in the neuroactive steroid solid dispersion is present in an amorphous state with a particle size of ≤ 200 nm, and features good oral bioavailability.
Owner:BEIJING HORICIN BIOTECHNOLOGY CO LTD

Crystalline forms of neuroactive steroids

The present disclosure relates to Compound 1 as well as crystalline solid forms and solid dosage forms thereof. The present disclosure also provides methods of making and using the crystalline solid forms of Compound 1, as well as solid dosage forms thereof. # imgabs0 # (compound 1)
Owner:SAGE THERAPEUTICS INC

Crystal Forms of Neuroactive Steroids

The present disclosure relates to a crystalline solid form of Compound 1. The present disclosure also provides a method for preparing the crystalline solid form of Compound 1. In a first aspect, the present disclosure provides a crystalline form of Compound 1, wherein the crystalline form is Crystal Form C, and Form C is characterized by an XRPD pattern comprising peaks at 12.0 ± 0.2, 15.1 ± 0.2, and 21.3 ± 0.2 degrees 2θ. In a second aspect, the present disclosure provides a solid dosage form comprising Crystal Form C of Compound 1 disclosed herein and at least one pharmaceutically acceptable carrier. JPEG2025523826000018.jpg3067
Owner:SAGE THERAPEUTICS INC